Acute Phase ResponseNCT03741023
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery
A study testing Blood draw (venipuncture or fingerstick) in people with Acute Phase Response, run by Vanderbilt University Medical Center at 1 site in United States.
Trial summary
The purpose of the proposed study is to test these hypotheses through the following aims: 1. To determine if early plasmin activation following severe injury correlates with SIRS, TIC and complications throughout convalescence in both trauma and surgical patients. 2. Read more about this study
- Who is it for?
- Ages 2 months and olderHealthy volunteers can take part
- Conditions the study is for
- Acute Phase Response
- What is being tested?
- Blood draw (venipuncture or fingerstick)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 320 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Dec 2019to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 months and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- None
- Arm 2: Invasive Elective Surgical Patients Inclusion criteria
- Any patient admitted for an invasive elective surgery associated with high blood loss or a high risk of vascular complications at VUMC/VCH. Enrollment will be at the discretion of the attending physician
- This may include, but is not limited to, orthopedic and vascular surgery patients
- Patients ages 2 months and older Exclusion criteria
- None
Show all 14Show fewer
- Arm 3: Healthy Volunteers Inclusion criteria
- Volunteers should be male or female
- Age 18-70 years of age
- Weight greater than 110lbs
- Chronic medical conditions such as: diabetes, hypertension, high cholesterol, rheumatologic disorders, infections, etc.
- No history of recent traumatic injury (within the past year)
- Pregnant females or people on hormone replacement therapy
- People on any anticoagulant medication or NSAIDS
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Vanderbilt Univeristy Medical Center
Nashville, Tennessee, 37232
About this study
Official title: Disorders of the Acute Phase Response Accelerated by Plasmin Activation Following Trauma and Invasive Surgery: A Prospective Study
The purpose of the proposed study is to test these hypotheses through the following aims:
- To determine if early plasmin activation following severe injury correlates with SIRS, TIC and complications throughout convalescence in both trauma and surgical patients.
- To determine if early plasmin activation following severe injury correlates with plasminogen consumption and poor plasmin activity later in convalescence.
Read the detailed description
Significance: Severe injury is a leading cause of death and disability worldwide, affecting approximately 2.8 million individuals and accounting for over 200,000 deaths annually across the United States1,2,3. Large cohort studies have demonstrated that approximately 64% of trauma-related deaths are due to complications including thrombosis, bleeding, infection, and organ dysfunction, and each complication corresponds with an 8% increase in risk of mortality4. While advances in critical care medicine have significantly improved the initial survival from traumatic injuries, the proportion of morbidity and mortality from complications experienced during traumatic convalescence has correspondingly skyrocketed. Early in convalescence, these patients are at risk of developing life-threatening complications instigated by trauma induced coagulopathy (TIC) and systemic inflammatory response syndrome (SIRS). Specifically, approximately 40% of patients with severe injuries develop TIC and approximately 70% develop SIRS5,6. While these conditions individually increase the risk of secondary sequelae, in concurrence, they dramatically increase the risk of bleeding, thrombosis, infection, and multi-organ dysfunction syndrome (MODS)7,8,9. Later in convalescence, patients experiencing severe injury are at risk of suffering complications from pathologic tissue homeostasis and repair. For example, depending on the injury, 25-65% of severely injured patients' rehabilitation and quality of life are limited by poor bone health, including the development of osteoporosis, impaired bone healing, and/or the development of heterotopic ossification10,11,12. Together, early and late complications of convalescence reportedly account for over $671 billion in healthcare expenditure and disability losses yearly1. Thus, there is an unmet need for improved therapeutic and diagnostic measures for these patients to prevent or treat complications of early and late convalescence.
The Acute Phase Response (APR): Following injury, the APR resolves the four principle problems provoked by disruption of tissue: bleeding, pathogen invasion, tissue hypoxia, and tissue dysfunction. After an isolated injury, e.g., femur fracture, the APR follows a predictable and quantifiable time-course with minimal risk of complications (Figure 1A). The survival phase contains the injury and prevents infection through hemostasis (fibrin deposition) and acute inflammation. The later repair phase effectively removes damaged tissue, regenerates new tissue, and restores function. Severe trauma derails the survival-APR, provoking complications in both in early and late convalescence (Figure 1B). In order to prevent exsanguination, severe trauma must provoke an adequate survival-APR in proportion to the severity of the injury. However, unrestrained and prolonged activation of coagulation and survival-inflammation lead to the development of TIC and SIRS and significantly increasing the risk of bleeding, thrombosis, and MODS6,5,8. Additionally, if a patient persists within the survival-APR for an extended period of time, the prolonged activation of cellular inflammation promotes disorders of tissue homeostasis, e.g., osteoporosis, and delays the transition to the repair-APR, stalling or preventing healing tissue and crippling recovery in these patients13,14. Therefore, APR complications are mechanistically linked, that is, dysfunction of the survival-APR contributes to dysfunction of the repair-APR. Although there are many reports suggesting potential molecular determinants of a dysfunctional APR, the primary molecular targets driving this phenomenon are unknown.
Severe Trauma-Provoked Changes in Plasmin Activity: Plasmin is converted from its zymogen, plasminogen, by its activators: tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). While plasmin is a multifunctional protease, its canonical role is the degradation of fibrin (fibrinolysis). While fibrinolysis occurs during the repair-APR following an isolated injury, a severe injury provokes early hyperactivation of plasmin (Figure 2)15,16. Fibrinolysis was first observed by anatomist Giovanni Morgagni and surgeon John Hunter in the late 1700s during autopsies of individuals that suffered traumatic injuries17,18. Both Morgagni and Hunter noted that blood from these individuals strangely did not clot. It was later determined that blood clots formed following traumatic injury or invasive surgery spontaneously dissolved, leading to the discovery of plasmin.
The immediate and most-recognized clinical consequence of this inappropriate hyperfibrinolysis is bleeding, as the degradation of fibrin opposes effective hemostasis19. The clinical significance of injury- induced hyperfibrinolysis was propelled by improvements in critical care medicine that permitted not only survival of previously fatal traumatic injuries, but also invasive, elective surgical procedures through the use of antifibrinolytic therapeutics. Specifically, recent clinical studies in >40,000 trauma patients have demonstrated that prevention of plasmin activation by antifibrinolytics (e.g., aminocaproic acid (Amicar), tranexamic acid (TXA)) significantly reduced blood loss and increased survival when administered early after injury20,21. Thus, it has been established that inappropriate, early plasmin activation (hyperfibrinolysis) is a significant cause of bleeding and mortality following severe injury19,16.
Pathologic Fibrinolysis - Hemorrhage is the Tip of the Iceberg: Both hyperfibrinolysis and hypofibrinolysis occur following trauma and have been associated with complications throughout convalescence22,23, indicating that plasmin's biologic role following injury is more complex than previously understood. Indeed, since the initial investigations of plasmin's role in bleeding, our knowledge of the biological role of plasmin has greatly expanded beyond its role in hemostasis. Currently, it is recognized that plasmin is activated during virtually all tissue repair, where it degrades intra- and extravascular fibrin24,25. In addition to fibrinolysis, plasmin also acts through non-canonical pathways to promote tissue repair including programming and migration of macrophages and progenitor cells, growth factor activation, and promotion of angiogenesis26,27,28,29. Additionally, plasmin stimulates an acute inflammatory response, promoting tissue regeneration30,31,32. Thus, plasmin is essential for tissue maintenance and repair. Specifically, our lab has extended this premise by determining that plasmin is essential for proper bone homeostasis, as well as bone and muscle repair33,34,35. Thus, following trauma, the biological role of plasmin is not limited to intravascular activity and bleeding. Instead, it plays well defined, albeit less understood, roles in pro- and anti-inflammatory responses, tissue homeostasis, and repair of virtually all tissues. While these studies would suggest that plasmin plays beneficial role in recovery following trauma, judicious prevention of early plasmin activation is clearly beneficial in preventing life threatening hemorrhage.
The purpose of the proposed study is to test these hypotheses through the following aims:
- To determine if early plasmin activation following severe injury correlates with SIRS, TIC and complications throughout convalescence in both trauma and surgical patients.
- To determine if early plasmin activation following severe injury correlates with plasminogen consumption and poor plasmin activity later in convalescence.
- Conditions
- Acute Phase Response
- Being tested
- Blood draw (venipuncture or fingerstick)
- Medical subject headings
- Acute-Phase Reaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood draw (venipuncture or fingerstick)Procedure or surgery
Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
| Study group | Role | What they receive |
|---|---|---|
| Trauma Patients | Other | During Hospitalization:
Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population.
Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury. Receives: Procedure: Blood draw (venipuncture or fingerstick) |
| Invasive Elective Surgery Patients | Other | During Hospitalization:
Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients <7 years of age (~3% total blood volume).
Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery. Receives: Procedure: Blood draw (venipuncture or fingerstick) |
| Healthy Volunteers | Other | Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit. Receives: Procedure: Blood draw (venipuncture or fingerstick) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interleukin-6 (IL-6)
A change in Interleukin-6 (IL-6) lab value following traumatic injuries or traumatic elective surgeries will be used to determine change in systematic inflammation.
Measured: During hospitalization (approximately 7-21 days)
Thrombin-Antithrombin (TAT) Complex
A change in the Thrombin-antithrombin (TAT) complex following traumatic injuries or traumatic elective surgeries will be used to determine change in coagulation.
Measured: During hospitalization (approximately 7-21 days)
D-Dimer
A change in d-dimer lab value following traumatic injuries or traumatic elective surgeries will be used to determine change in fibrinolysis.
Measured: During hospitalization (approximately 7-21 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2018
- Study start12 Dec 2019
- Primary completion1 Jan 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Phase ResponseStudies of the same condition, open and under way.
- More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 320 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jon Schoenecker, Vanderbilt University Medical Center
- Investigators
- Jonathan Schoenecker, MD, PhD, Principal investigator, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03741023
- Sponsor's protocol ID
- 181982
- Status last verified
- Mar 2026
- First submitted
- 31 Oct 2018
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Gibson BHY, Duvernay MT, McKeithan LJ, Benvenuti TA, Warhoover TA, Martus JE, Mencio GA, Emerson BR, Moore-Lotridge SN, Borst AJ, Schoenecker JG. Variable Response to Antifibrinolytics Correlates with Blood-loss and Transfusion in Posterior Spinal Fusion. Spine Deform. 2022 Jul;10(4):841-851. doi: 10.1007/s43390-022-00489-6. Epub 2022 Mar 5.
PubMed 35247191
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Disorders of the Acute Phase Response Accelerated by Plasmin Activation Following Trauma and Invasive Surgery: A Prospective Study
- ClinicalTrials.gov ID
- NCT03741023
- Acronym / sponsor ID
- 181982
- Conditions
- Acute Phase Response
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 320 participants (estimated)
- Lead sponsor
- Vanderbilt University Medical CenterUniversity, hospital or other
- Study start
- 12 Dec 2019 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 14 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the proposed study is to test these hypotheses through the following aims:
- To determine if early plasmin activation following severe injury correlates with SIRS, TIC and complications throughout convalescence in both trauma and surgical patients.
- To determine if early plasmin activation following severe injury correlates with plasminogen consumption and poor plasmin activity later in convalescence.
Detailed description
Significance: Severe injury is a leading cause of death and disability worldwide, affecting approximately 2.8 million individuals and accounting for over 200,000 deaths annually across the United States1,2,3. Large cohort studies have demonstrated that approximately 64% of trauma-related deaths are due to complications including thrombosis, bleeding, infection, and organ dysfunction, and each complication corresponds with an 8% increase in risk of mortality4. While advances in critical care medicine have significantly improved the initial survival from traumatic injuries, the proportion of morbidity and mortality from complications experienced during traumatic convalescence has correspondingly skyrocketed. Early in convalescence, these patients are at risk of developing life-threatening complications instigated by trauma induced coagulopathy (TIC) and systemic inflammatory response syndrome (SIRS). Specifically, approximately 40% of patients with severe injuries develop TIC and approximately 70% develop SIRS5,6. While these conditions individually increase the risk of secondary sequelae, in concurrence, they dramatically increase the risk of bleeding, thrombosis, infection, and multi-organ dysfunction syndrome (MODS)7,8,9. Later in convalescence, patients experiencing severe injury are at risk of suffering complications from pathologic tissue homeostasis and repair. For example, depending on the injury, 25-65% of severely injured patients' rehabilitation and quality of life are limited by poor bone health, including the development of osteoporosis, impaired bone healing, and/or the development of heterotopic ossification10,11,12. Together, early and late complications of convalescence reportedly account for over $671 billion in healthcare expenditure and disability losses yearly1. Thus, there is an unmet need for improved therapeutic and diagnostic measures for these patients to prevent or treat complications of early and late convalescence.
The Acute Phase Response (APR): Following injury, the APR resolves the four principle problems provoked by disruption of tissue: bleeding, pathogen invasion, tissue hypoxia, and tissue dysfunction. After an isolated injury, e.g., femur fracture, the APR follows a predictable and quantifiable time-course with minimal risk of complications (Figure 1A). The survival phase contains the injury and prevents infection through hemostasis (fibrin deposition) and acute inflammation. The later repair phase effectively removes damaged tissue, regenerates new tissue, and restores function. Severe trauma derails the survival-APR, provoking complications in both in early and late convalescence (Figure 1B). In order to prevent exsanguination, severe trauma must provoke an adequate survival-APR in proportion to the severity of the injury. However, unrestrained and prolonged activation of coagulation and survival-inflammation lead to the development of TIC and SIRS and significantly increasing the risk of bleeding, thrombosis, and MODS6,5,8. Additionally, if a patient persists within the survival-APR for an extended period of time, the prolonged activation of cellular inflammation promotes disorders of tissue homeostasis, e.g., osteoporosis, and delays the transition to the repair-APR, stalling or preventing healing tissue and crippling recovery in these patients13,14. Therefore, APR complications are mechanistically linked, that is, dysfunction of the survival-APR contributes to dysfunction of the repair-APR. Although there are many reports suggesting potential molecular determinants of a dysfunctional APR, the primary molecular targets driving this phenomenon are unknown.
Severe Trauma-Provoked Changes in Plasmin Activity: Plasmin is converted from its zymogen, plasminogen, by its activators: tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). While plasmin is a multifunctional protease, its canonical role is the degradation of fibrin (fibrinolysis). While fibrinolysis occurs during the repair-APR following an isolated injury, a severe injury provokes early hyperactivation of plasmin (Figure 2)15,16. Fibrinolysis was first observed by anatomist Giovanni Morgagni and surgeon John Hunter in the late 1700s during autopsies of individuals that suffered traumatic injuries17,18. Both Morgagni and Hunter noted that blood from these individuals strangely did not clot. It was later determined that blood clots formed following traumatic injury or invasive surgery spontaneously dissolved, leading to the discovery of plasmin.
The immediate and most-recognized clinical consequence of this inappropriate hyperfibrinolysis is bleeding, as the degradation of fibrin opposes effective hemostasis19. The clinical significance of injury- induced hyperfibrinolysis was propelled by improvements in critical care medicine that permitted not only survival of previously fatal traumatic injuries, but also invasive, elective surgical procedures through the use of antifibrinolytic therapeutics. Specifically, recent clinical studies in >40,000 trauma patients have demonstrated that prevention of plasmin activation by antifibrinolytics (e.g., aminocaproic acid (Amicar), tranexamic acid (TXA)) significantly reduced blood loss and increased survival when administered early after injury20,21. Thus, it has been established that inappropriate, early plasmin activation (hyperfibrinolysis) is a significant cause of bleeding and mortality following severe injury19,16.
Pathologic Fibrinolysis - Hemorrhage is the Tip of the Iceberg: Both hyperfibrinolysis and hypofibrinolysis occur following trauma and have been associated with complications throughout convalescence22,23, indicating that plasmin's biologic role following injury is more complex than previously understood. Indeed, since the initial investigations of plasmin's role in bleeding, our knowledge of the biological role of plasmin has greatly expanded beyond its role in hemostasis. Currently, it is recognized that plasmin is activated during virtually all tissue repair, where it degrades intra- and extravascular fibrin24,25. In addition to fibrinolysis, plasmin also acts through non-canonical pathways to promote tissue repair including programming and migration of macrophages and progenitor cells, growth factor activation, and promotion of angiogenesis26,27,28,29. Additionally, plasmin stimulates an acute inflammatory response, promoting tissue regeneration30,31,32. Thus, plasmin is essential for tissue maintenance and repair. Specifically, our lab has extended this premise by determining that plasmin is essential for proper bone homeostasis, as well as bone and muscle repair33,34,35. Thus, following trauma, the biological role of plasmin is not limited to intravascular activity and bleeding. Instead, it plays well defined, albeit less understood, roles in pro- and anti-inflammatory responses, tissue homeostasis, and repair of virtually all tissues. While these studies would suggest that plasmin plays beneficial role in recovery following trauma, judicious prevention of early plasmin activation is clearly beneficial in preventing life threatening hemorrhage.
The purpose of the proposed study is to test these hypotheses through the following aims:
- To determine if early plasmin activation following severe injury correlates with SIRS, TIC and complications throughout convalescence in both trauma and surgical patients.
- To determine if early plasmin activation following severe injury correlates with plasminogen consumption and poor plasmin activity later in convalescence.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Trauma Patients | Other | Procedure: Blood draw (venipuncture or fingerstick)During Hospitalization: Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population. Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury. |
| Invasive Elective Surgery Patients | Other | Procedure: Blood draw (venipuncture or fingerstick)During Hospitalization: Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients <7 years of age (~3% total blood volume). Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery. |
| Healthy Volunteers | Other | Procedure: Blood draw (venipuncture or fingerstick)Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit. |
Who may qualify
- Ages
- 2 months and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (14 listed)
- None
- Arm 2: Invasive Elective Surgical Patients Inclusion criteria
- Any patient admitted for an invasive elective surgery associated with high blood loss or a high risk of vascular complications at VUMC/VCH. Enrollment will be at the discretion of the attending physician
- This may include, but is not limited to, orthopedic and vascular surgery patients
- Patients ages 2 months and older Exclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood draw (venipuncture or fingerstick)Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population. | Procedure or surgery | Healthy Volunteers, Invasive Elective Surgery Patients, Trauma Patients |
Primary outcome
Interleukin-6 (IL-6)
Time frame: During hospitalization (approximately 7-21 days)
A change in Interleukin-6 (IL-6) lab value following traumatic injuries or traumatic elective surgeries will be used to determine change in systematic inflammation.
Thrombin-Antithrombin (TAT) Complex
Time frame: During hospitalization (approximately 7-21 days)
A change in the Thrombin-antithrombin (TAT) complex following traumatic injuries or traumatic elective surgeries will be used to determine change in coagulation.
D-Dimer
Time frame: During hospitalization (approximately 7-21 days)
A change in d-dimer lab value following traumatic injuries or traumatic elective surgeries will be used to determine change in fibrinolysis.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Derived from this study: PubMed 35247191Gibson BHY, Duvernay MT, McKeithan LJ, Benvenuti TA, Warhoover TA, Martus JE, Mencio GA, Emerson BR, Moore-Lotridge SN, Borst AJ, Schoenecker JG. Variable Response to Antifibrinolytics Correlates with Blood-loss and Transfusion in Posterior Spinal Fusion. Spine Deform. 2022 Jul;10(4):841-851. doi: 10.1007/s43390-022-00489-6. Epub 2022 Mar 5.
- Individual participant dataSharing planned: No
Related trials for Acute Phase Response
RecruitingPhase 2
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Core Binding Factor Acute Myeloid Leukemia
RecruitingPhase 1/2
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
Systemic Inflammatory Response Syndrome
RecruitingObservational study
Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction
RecruitingPhase 2
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Sepsis, Acute Kidney Injury
RecruitingPhase 4
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Sepsis and Septic Shock, Acute Respiratory Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jonathan Schoenecker, MD, PhD principal investigator
Vanderbilt University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood draw (venipuncture or fingerstick) in people with Acute Phase Response, run by Vanderbilt University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interleukin-6 (IL-6) (time frame: During hospitalization (approximately 7-21 days)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03741023, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.